再鼎醫藥股票討論區

Zai Lab's share price drops despite revenue growth, hinting at profitability issues. The company may need to raise capital soon. Shareholders have faced an annual loss of 8% over the past five years.

Market expectations suggest a decline in Zai Lab's future revenue, possibly suppressing the P/S. Investors appear to anticipate limited growth, paying less for the stock. These conditions may continue to hinder the share price.

A team of US regulators is in the final stages of discussions with two Hong Kong accounting firms regarding their audits of mainland Chinese companies facing possible delisting from US exchanges, according to two sources familiar with the situation.
This indicates the unprecedented review is nearing its end, and a report may come as soon as the end of this year, potenti...